APVO

Company Overview — What Does Aptevo Therapeutics Inc. Do?

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Aptevo Therapeutics Inc. (APVO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Marvin L. White and employs approximately 50 people, headquartered in SEATTLE, Washington. With a market capitalization of $4M, APVO is one of the notable companies in the Healthcare sector.

Aptevo Therapeutics Inc. (APVO) Stock Rating — Avoid (April 2026)

As of April 2026, Aptevo Therapeutics Inc. receives a Avoid rating with a composite score of 25.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.APVO ranks #4,136 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aptevo Therapeutics Inc. ranks #729 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

APVO Stock Price and 52-Week Range

Aptevo Therapeutics Inc. (APVO) currently trades at $4.25. The stock lost $0.12 (2.7%) in the most recent trading session. The 52-week high for APVO is $13.11, which means the stock is currently trading -67.6% from its annual peak. The 52-week low is $0.24, putting the stock 1652.6% above its annual trough. Recent trading volume was 9K shares, suggesting relatively thin trading activity.

Is APVO Overvalued or Undervalued? — Valuation Analysis

Aptevo Therapeutics Inc. (APVO) carries a value factor score of 6/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.28x, versus the sector average of 2.75x.

At current multiples, Aptevo Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aptevo Therapeutics Inc. Profitability — ROE, Margins, and Quality Score

Aptevo Therapeutics Inc. (APVO) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -145.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -92.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

APVO Debt, Balance Sheet, and Financial Health

Aptevo Therapeutics Inc. has a debt-to-equity ratio of 56.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.82x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $21M.

APVO has a beta of 9.06, meaning it is more volatile than the broader market — a $10,000 investment in APVO would be expected to move 806.5% more than the S&P 500 on any given day. The stability factor score for Aptevo Therapeutics Inc. is 4/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aptevo Therapeutics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aptevo Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-87.27. Net income for the quarter was $-25M. Operating income came in at $-26M.

In FY 2025, Aptevo Therapeutics Inc. reported revenue of N/A and earnings per share (EPS) of $-87.27. Net income for the quarter was $-26M. Operating income came in at $-26M.

In Q3 2025, Aptevo Therapeutics Inc. reported revenue of N/A and earnings per share (EPS) of $-2.23. Net income for the quarter was $-8M. Operating income came in at $-8M.

In Q2 2025, Aptevo Therapeutics Inc. reported revenue of N/A and earnings per share (EPS) of $-8.40. Net income for the quarter was $-6M. Operating income came in at $-6M.

Over the past 8 quarters, Aptevo Therapeutics Inc. has reported varying levels of revenue. Investors analyzing APVO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

APVO Dividend Yield and Income Analysis

Aptevo Therapeutics Inc. (APVO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

APVO Momentum and Technical Analysis Profile

Aptevo Therapeutics Inc. (APVO) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

APVO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aptevo Therapeutics Inc. (APVO) ranks #729 out of 838 stocks based on the Blank Capital composite score. This places APVO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing APVO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full APVO vs S&P 500 (SPY) comparison to assess how Aptevo Therapeutics Inc. stacks up against the broader market across all factor dimensions.

APVO Next Earnings Date

No upcoming earnings date has been announced for Aptevo Therapeutics Inc. (APVO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy APVO? — Investment Thesis Summary

The quantitative profile for Aptevo Therapeutics Inc. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 6/100 indicates premium valuation. Price momentum is positive at 63/100, suggesting the trend favors buyers. High volatility (stability score 4/100) increases portfolio risk.

In summary, Aptevo Therapeutics Inc. (APVO) earns a Avoid rating with a composite score of 25.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on APVO stock.

Related Resources for APVO Investors

Explore more research and tools: APVO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare APVO head-to-head with peers: APVO vs AZN, APVO vs SLGL, APVO vs VMD.